Navigation Links
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
Date:8/16/2012

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0945797/Commercializing-Breast-Cancer-Drugs-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.

BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.

* Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.

* The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.

* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.

* Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodiesbased breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.

* The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents 1 Executive Summary 3

2 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 6

3 Methodology 7

3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7

4 Table of Contents 94.1 List of Figures 234.2 List of Tables 23

5 Introduction 32

5.1 The Scope of this Report 32

5.2 Definitions 35

5.3 Abbreviations 35

6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 366.1 Drug Repositioning in Oncology 366.2 Introduction to Targets of Breast Cancer Drugs 376.2.1 Acid Phosphatase Activity Targets 456.2.2 Auxiliary Transport Protein Activity Targets 466.2.3 Catalytic Activity Targets 476.2.4 Cell Adhesion Molecule Activity Targets 616.2.5 Chaperone Activity Targets 766.2.6 Chemokine Activity Targets 816.2.7 Complement Activity Targets 836.2.8 Cysteine-type Peptidase Activity Targets 866.2.9 Cytokine Activity Targets 946.2.10 DNA Binding Targets 1026.2.11 DNA Repair Protein Targets 1046.2.12 DNA Topoisomerase Activity Targets 1066.2.13 DNA-directed DNA Polymerase Activity Targets 1116.2.14 Extracellular Ligand-gated Ion Channel Activity Targets 1126.2.15 Extracellular Matrix Structural Constituent Targets 1146.2.16 G-protein Coupled Receptor Activity Targets 1156.2.17 Glutathione Transferase Activity Targets 1256.2.18 Growth Factor Activity Targets 1276.2.19 Growth Factor Binding Targets 1346.2.20 Hormone Activity Targets 1356.2.21 Intracellular Ligand-gated Ion Channel Activity Targets 1366.2.22 Ion Channel Activity Targets 1376.2.23 Isomerase Activity Targets 1386.2.24 Kinase Activity Targets 1396.2.25 Kinase Binding Targets 1516.2.26 Kinase Regulator Activity Targets 1526.2.27 Ligand-dependent Nuclear Receptor Activity Targets 1566.2.28 Ligase Activity Targets 1596.2.29 Lipid Kinase Activity Targets 1666.2.30 Lipid Phosphatase Activity Targets 1756.2.31 Metallopeptidase Activity Targets 1766.2.32 Molecular Function Unknown Targets 1806.2.33 Motor Activity Targets 1906.2.34 Oxidoreductase Activity Targets 1926.2.35 Peptidase Activity Targets 2016.2.36 Peptide Hormone Targets 2106.2.37 Peroxidase Activity Targets 2116.2.38 Phosphoric Diester Hydrolase Activity Targets 2126.2.39 Protein Binding Targets 2156.2.40 Protein Serine/Threonine Kinase Activity Targets 2206.2.41 Protein Threonine/Tyrosine Kinase Activity Targets 2586.2.42 Protein-tyrosine Kinase Activity Targets 2636.2.43 Receptor Activity Targets 2746.2.44 Receptor Binding Targets 2916.2.45 Receptor Signaling Complex Scaffold Activity Targets 2996.2.46 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 3036.2.47 RNA Binding Targets 3056.2.48 RNA-directed DNA Polymerase Activity Targets 3066.2.49 Serine-type Peptidase Activity Targets 3076.2.50 Structural Constituent of Cytoskeleton Targets 3106.2.51 Structural Molecule Activity Targets 3136.2.52 Superoxide Dismutase Activity Targets 3156.2.53 T Cell Receptor Activity Targets 3176.2.54 Transcription Factor Activity Targets 3186.2.55 Transcription Regulator Activity Targets 3486.2.56 Transferase Activity Targets 3596.2.57 Translation Regulator Activity Targets 3626.2.58 Transmembrane Receptor Activity Targets 3636.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3676.2.60 Transporter Activity Targets 4156.2.61 Voltage-gated Ion Channel Activity Targets 4226.2.62 Other Targets 4236.3 Mutation Profiles of Breast Cancer Drug Targets 4266.3.1 Targets of Breast Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 4266.4 Breast Cancer Therapeutics is Stimulated by Available Structure Data on Targets 4326.5 Target-Target Interactions among Identified Targets of Breast Cancer Drugs 4376.6 The Drug-Target Competitive Landscape 4426.7 Protein Expression Levels of Identified Targets of Breast Cancer Drugs 4476.8 Pathway Assessment of Breast Cancer Drugs 4516.8.1 Tools for Analysis of Cancer Pathways 4526.8.2 Pathway Assessment 453

7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development 523

7.1 Marketed: New and Unique Drug Target Strategies of Breast Cancer Drugs 526

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 528

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 530

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 537

7.5 Preclinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 541

7.6 Drug Target Strategies of Suspended or Terminated Breast Cancer Drugs 545

7.7 Target Strategy Development Profiles of Breast Cancer Drugs 549

7.7.1 Marketed 554

7.7.2 Phase III 574

7.7.3 Phase II 583

7.7.4 Phase I 660

7.7.5 Preclinical 695

7.7.6 No Data 734

7.7.7 Suspended 735

7.7.8 Ceased 738

7.8 The Competition Through Close Mechanistic Approximation of Breast Cancer Drugs 786

8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy 7988.1 Small Molecules 8008.1.1 Background 8008.1.2 Target Strategies of Small Molecule Drugs 8018.2 Peptide & Protein Drugs 8178.2.1 Background 8178.2.2 Target Strategies of Peptide and Protein Drugs 8188.3 Antibodies 8248.3.1 Background 8248.3.2 Target Strategies of Antibody Drugs 8248.4 Nucleic Acid Therapies 8298.4.1 Background 8298.4.2 Target Strategies of Nucleic Acid Drugs 8308.5 Cell & Gene Therapy 8328.5.1 Background 8328.5.2 Target Strategies of Cell and Gene Therapy Drugs 8338.6 Drug Delivery and Nanotechnology 8388.6.1 Background 8388.6.2 Target Strategies of Reformulated Drugs 8388.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 842

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator 851

9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 857

9.2 Company Facts and Ranking 860

9.3 Competitive Fall-Out Assessment 867

9.4 A&G Pharmaceutical 869

9.5 Abbott 871

9.6 Abiogen 876

9.7 Access 880

9.8 Adherex 883

9.9 Advanomics 885

9.10 Advaxis 889

9.11 AEgera 893

9.12 AEterna Zentaris 895

9.13 Affibody 897

9.14 Affimed Therapeutics 901

9.15 Alchemia 904

9.16 Alethia Biotherapeutics 910

9.17 Allos Therapeutics 912

9.18 Alnis Biosciences 914

9.19 AlphaVax 918

9.20 Alseres Pharmaceuticals 923

9.21 Amgen 926

9.22 AngioChem 934

9.23 Antisoma 938

9.24 Aphios 943

9.25 Ariad 948

9.26 ArQule 951

9.27 Array BioPharma 955

9.28 Ascend Therapeutics 960

9.29 Ascepion Pharmaceuticals 963

9.30 Astellas 965

9.31 Astex Pharmaceuticals 970

9.32 AstraZeneca 974

9.33 Attenuon 985

9.34 AVI BioPharma 987

9.35 Basilea Pharmaceutica 989

9.36 Bavarian Nordic 993

9.37 Bayer 997

9.38 Beta Pharma 1004

9.39 Betagenon 1007

9.40 Biogen Idec 1009

9.41 BioMarin 1013

9.42 Bionovo 1015

9.43 BioSante 1018

9.44 Biotecnol 1021

9.45 Boehringer Ingelheim 1025

9.46 Bristol-Myers Squibb 1028

9.47 BTG 1039

9.48 Callisto Pharmaceuticals 1044

9.49 Cancer Research Technology 1048

9.50 Cel-Sci 1052

9.51 Celgene 1054

9.52 Cell Therapeutics 1059

9.53 Celldex Therapeutics 1065

9.54 Celltrion 1067

9.55 Celsion 1071

9.56 Celtic Pharma 1075

9.57 Center of Molecular Immunology 1077

9.58 Chemokine Therapeutics 1080

9.59 Chiesi 1083

9.60 Chong Kun Dang 1086

9.61 CompleGen 1090

9.62 Curis 1092

9.63 Cyclacel 1095

9.64 Cylene Pharmaceuticals 1097

9.65 Cynvec 1099

9.66 CytImmune Sciences 1101

9.67 Cytokinetics 1105

9.68 CytRx 1108

9.69 Daiichi Sankyo 1112

9.70 Dainippon Sumitomo Pharma 1117

9.71 Debiopharm 1121

9.72 Dendreon 1124

9.73 Domainex 1129

9.74 Dong-A 1131

9.75 Dongkook Pharm 1135

9.76 Douglas 1138

9.77 ECI 1141

9.78 Eisai 1143

9.79 Elara Pharmaceuticals 1148

9.80 ElexoPharm 1151

9.81 Eli Lilly 1153

9.82 Endoceutics 1161

9.83 Enkam Pharmaceuticals 1164

9.84 EntreMed 1166

9.85 Enzon 1168

9.86 Epeius Biotechnologies 1171

9.87 EpiCept 1173

9.88 Epizyme 1177

9.89 Esperance Pharmaceuticals 1179

9.90 Etubics 1181

9.91 Eucodis 1185

9.92 Exelixis 1188

9.93 Expression Drug Designs 1195

9.94 Formula Pharmaceuticals 1197

9.95 Fresenius 1200

9.96 Galectin Therapeutics 1204

9.97 Galena Biopharma 1208

9.98 Genentech 1213

9.99 Generex 1217

9.100 Genmab 1221

9.101 Genta 1226

9.102 GenVec 1228

9.103 Geron 1230

9.104 Gilead Sciences 1233

9.105 GlaxoSmithKline 1237

9.106 GlyTag 1244

9.107 Got-a-Gene 1246

9.108 Gradalis 1250

9.109 Harbor BioSciences 1252

9.110 Heidelberg Pharma 1255

9.111 Hoffmann-La Roche 1258

9.112 Hospira 1271

9.113 Idera Pharmaceuticals 1275

9.114 Immunocore 1278

9.115 ImmunoGen 1281

9.116 Immunomedics 1285

9.117 ImmuPharma 1289

9.118 Immutep 1291

9.119 Incyte Corporation 1293

9.120 Inex 1296

9.121 Infinity Pharmaceuticals 1300

9.122 Innate Pharma 1303

9.123 InNexus Biotechnology 1305

9.124 Inovio 1309

9.125 Insmed 1311

9.126 Insys Therapeutics 1314

9.127 Intarcia Therapeutics 1320

9.128 Intezyne Technologies 1323

9.129 Intradigm 1327

9.130 Introgen Therapeutics 1330

9.131 Ipsen 1334

9.132 Isis Pharmaceuticals 1338

9.133 Jina Pharmaceuticals 1340

9.134 Johnson & Johnson 1343

9.135 Kiadis 1345

9.136 Kinex 1348

9.137 Kyowa Hakko Kirin 1350

9.138 Leo 1356

9.139 Ligand 1358

9.140 Lorus Therapeutics 1362

9.141 MacroGenics 1364

9.142 Marillion Pharmaceuticals 1368

9.143 Marina Biotech 1371

9.144 Meda 1374

9.145 Medarex 1379

9.146 MediGene 1382

9.147 MedImmune 1386

9.148 Mediolanum 1389

9.149 Menarini 1392

9.150 Merck & Co 1396

9.151 Merck KGaA 1401

9.152 Merrimack 1403

9.153 MetaMol Theranostics 1407

9.154 Mologen 1410

9.155 Nektar Therapeutics 1413

9.156 Nemod Biotherapeutics 1416

9.157 Neurocrine Biosciences 1419

9.158 NexGenix Pharmaceuticals 1421

9.159 Nidus Laboratories 1425

9.160 NIH – The US National Institute of Health 1429

9.161 Nimbus Discovery 1432

9.162 Nippon Kayaku 1434

9.163 Non-industrial Source 1437

9.164 Novartis 1441

9.165 Novogen 1453

9.166 Oasmia 1455

9.167 OncoGenex Pharmaceuticals 1457

9.168 Oncolix 1462

9.169 OncoMune 1465

9.170 Onconova 1469

9.171 Oncothyreon 1472

9.172 Oncozyme Pharma 1476

9.173 Orion Pharma 1478

9.174 OSI Pharmaceuticals 1481

9.175 Oxford BioMedica 1486

9.176 Pacific Biotech 1488

9.177 Paladin Labs 1491

9.178 PanaGin 1494

9.179 Pantarhei Bioscience 1496

9.180 Peregrine Pharmaceuticals 1499

9.181 Pfizer 1501

9.182 Pharmacyclics 1515

9.183 PharmaGap 1517

9.184 PharmaMar 1519

9.185 Pharmexa 1523

9.186 PheneX 1528

9.187 Philogen 1530

9.188 Pierre Fabre 1532

9.189 Piramal 1535

9.190 ProStrakan 1537

9.191 PTC Therapeutics 1539

9.192 R&R 1542

9.193 Radient Pharmaceuticals 1545

9.194 Raptor Pharmaceutical 1547

9.195 Receptor BioLogix 1549

9.196 Regeneron 1552

9.197 Regulon 1555

9.198 RESprotect 1557

9.199 Rigel 1559

9.200 Samyang 1561

9.201 Sanofi 1566

9.202 Santaris Pharma 1573

9.203 Sareum 1575

9.204 Savient Pharmaceuticals 1577

9.205 Schering-Plough 1580

9.206 SEEK 1583

9.207 Selvita 1586

9.208 Semafore Pharmaceuticals 1588

9.209 Shenogen 1590

9.210 Sigma-Tau 1594

9.211 Sirnaomics 1597

9.212 SRI International 1599

9.213 Sun Pharma Advanced Research 1604

9.214 Supratek Pharma 1608

9.215 Synageva BioPharma 1612

9.216 Synta Pharmaceuticals 1616

9.217 Taiho 1618

9.218 Taiwan Liposome Company 1622

9.219 Takeda 1626

9.220 Tapestry Pharmaceuticals 1628

9.221 TapImmune 1632

9.222 Targa Therapeutics 1634

9.223 Tau Therapeutics 1636

9.224 Taxolog 1640

9.225 Telik 1645

9.226 Teva 1649

9.227 Thallion Pharmaceuticals 1655

9.228 Therion Biologics 1657

9.229 to-BBB 1659

9.230 TopoTarget 1663

9.231 Tragara Pharmaceuticals 1666

9.232 Transgene 1668

9.233 Trion Pharma 1670

9.234 Vaccinex 1672

9.235 Vaxon Biotech 1674

9.236 Verastem 1677

9.237 Vernalis 1681

9.238 Vical 1684

9.239 Vion Pharmaceuticals 1687

9.240 VioQuest 1690

9.241 ViroMed 1693

9.242 ViroTarg 1697

9.243 Wilex 1699

9.244 Wyeth 1701

9.245 Xerion 1704

9.246 Xoma 1707

9.247 Yakult Honsha 1710

9.248 YM BioSciences 1713

9.249 Zensun 1716

9.250 Zydus Cadila 1719

10 Disclaimer 1724

11 Drug Index 1725

12 Company Index 1742

List of Figures Figure 1: Visualization of Target-Target Interactions among Targets of Breast Cancer Drugs 441

Figure 2: The Drug-Target Competitive Landscape of Breast Cancer Drugs - Large Cluster 443

Figure 3: The Drug-Target Competitive Landscape Breast Cancer Drugs - Smaller Clusters 444

Figure 4: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs – Larger Clusters 445

Figure 5: Head-to-Head Targeting Competitive Landscape of Breast Cancer Drugs – Smaller Clusters 446

Figure 6: Distribution of Compound Strategies among Breast Cancer Drugs 842

Figure 7: Primary Sub-cellular Localization of Drug Targets 843

Figure 8: Number of Companies per Ranking Level 862

List of Tables Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Breast Cancer Drug Pipeline by Stage of Development 32

Table 3: Head to Head Target Competition among Breast Cancer Drugs 32

Table 4: Overview of Drug Target Strategy Themes 37

Table 5: Terminally Ceased Targets of Breast Cancer Drugs 38

Table 6: Official Gene Symbol to Target Profle 39

Table 7: Mutation Frequencies of Breast Cancer Drug Targets 427

Table 8: Identity of Drug Targets with Available Biological Structures 432

Table 9: Number of Target-Target Interactions among Targets of Breast Cancer Drugs 438

Table 10: Available Protein Expression Profiles of Breast Cancer Drug Targets 447

Table 11: Pathway Summary 453

Table 12: Drug Targets without any Identified Assigned Pathways 453

Table 13: Pathway Profiles According to BioCarta of Breast Cancer Drug Targets 455

Table 14: Pathway Profiles According to KEGG of Breast Cancer Drug Targets 481

Table 15: Pathway Profiles According to NetPath of Breast Cancer Drug Targets 512

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 523

Table 17: Top Competitive Target Strategies of Breast Cancer Drugs 524

Table 18: New and Unique Target Strategies of Marketed Breast Cancer Drugs 526

Table 19: The Competition Through Close Mechanistic Approximation Between Breast Cancer Drugs Being Marketed 527

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Breast Cancer Drugs 528

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Breast Cancer Drugs 529

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Breast Cancer Drugs 530

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Breast Cancer Drugs 534

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Breast Cancer Drugs 537

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Breast Cancer Drugs 539

Table 26: New and Unique Target Strategies in Preclinical Development of Breast Cancer Drugs 541

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Breast Cancer Drugs 543

Table 28: Target Strategies of No Data, Suspended or Terminated Breast Cancer Drugs 545

Table 29: Connecting Target Strategy with Its Profile Identification Number 549

Table 30: The Competition Through Close Mechanistic Approximation Among Breast Cancer Drugs 786

Table 31: Overview of Compound Strategy Competition Among Breast Cancer Drugs 799

Table 32: Overview of the Competitive Landscape of Small Molecule Based Breast Cancer Drugs 801

Table 33: Competitive Comparison of Target Strategies of Small Molecule Breast Cancer Drugs 802

Table 34: Pursued Target Strategies of Small Molecule Drugs Based Breast Cancer Drugs 809

Table 35: Overview of the Competitive Landscape of Peptide Based Breast Cancer Drugs 818

Table 36: Competitive Comparison of Target Strategies of Peptide Based Breast Cancer Drugs 819

Table 37: Pursued Target Strategies of Peptide Based Breast Cancer Drugs 819

Table 38: Overview of the Competitive Landscape of Protein Based Breast Cancer Drugs 821

Table 39: Competitive Comparison of Target Strategies of Protein Based Breast Cancer Drugs 822

Table 40: Pursued Target Strategies of Protein Based Breast Cancer Drugs 822

Table 41: Overview of the Competitive Landscape of Antibody Based Breast Cancer Drugs 824

Table 42: Competitive Comparison of Target Strategies of Antibody Based Breast Cancer Drugs 825

Table 43: Pursued Target Strategies of Antibody Based Breast Cancer Drugs 826

Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Breast Cancer Drugs 830

Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Breast Cancer Drugs 831

Table 46: Pursued Target Strategies of Nucleic Acid Based Breast Cancer Drugs 831

Table 47: Potential Forms of Cell Therapy 832

Table 48: Vectors in Gene Therapy 833

Table 49: Overview of the Competitive Landscape of Cell Therapy Based Breast Cancer Drugs 833

Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Breast Cancer Drugs 834

Table 51: Pursued Target Strategies of Cell Therapy Based Breast Cancer Drugs 834

Table 52: Overview of the Competitive Landscape of Gene Therapy Based Breast Cancer Drugs 835

Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Breast Cancer Drugs 836

Table 54: Pursued Target Strategies of Gene Therapy Based Breast Cancer Drugs 836

Table 55:Overview of the Competitive Landscape of Reformulated Breast Cancer Drugs 838

Table 56: Competitive Comparison of Target Strategies of Reformulated Breast Cancer Drugs 839

Table 57: Pursued Target Strategies of Reformulated Breast Cancer Drugs 840

Table 58: Compound Strategies based on Sub-Cellular Localization of Breast Cancer Drug Targets 843

Table 59: Competitive Summary by Investigator of Breast Cancer Drug Development 851

Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Breast Cancer Drug Development 857

Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 861

Table 62: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified) 867

Table 63: A&G Pharmaceutical's Included Breast Cancer Drugs and Competitive Fall-Out 870

Table 64: Abbott's Included Breast Cancer Drugs and Competitive Fall-Out 873

Table 65: Abiogen's Included Breast Cancer Drugs and Competitive Fall-Out 879

Table 66: Access' Included Breast Cancer Drugs and Competitive Fall-Out 882

Table 67: Adherex's Included Breast Cancer Drugs and Competitive Fall-Out 884

Table 68: Advanomics' Included Breast Cancer Drugs and Competitive Fall-Out 888

Table 69: Advaxis' Included Breast Cancer Drugs and Competitive Fall-Out 892

Table 70: AEgera's Included Breast Cancer Drugs and Competitive Fall-Out 894

Table 71: AEterna Zentaris' Included Breast Cancer Drugs and Competitive Fall-Out 896

Table 72: Affibody's Included Breast Cancer Drugs and Competitive Fall-Out 900

Table 73: Affimed Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 903

Table 74: Alchemia's Included Breast Cancer Drugs and Competitive Fall-Out 907

Table 75: Alethia Biotherapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 911

Table 76: Allos Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 913

Table 77: Alnis Biosciences' Included Breast Cancer Drugs and Competitive Fall-Out 917

Table 78: AlphaVax's Included Breast Cancer Drugs and Competitive Fall-Out 921

Table 79: Alseres Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 925

Table 80: Amgen's Included Breast Cancer Drugs and Competitive Fall-Out 929

Table 81: AngioChem's Included Breast Cancer Drugs and Competitive Fall-Out 937

Table 82: Antisoma's Included Breast Cancer Drugs and Competitive Fall-Out 941

Table 83: Aphios' Included Breast Cancer Drugs and Competitive Fall-Out 946

Table 84: Ariad's Included Breast Cancer Drugs and Competitive Fall-Out 950

Table 85: ArQule's Included Breast Cancer Drugs and Competitive Fall-Out 953

Table 86: Array BioPharma's Included Breast Cancer Drugs and Competitive Fall-Out 958

Table 87: Ascend Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 962

Table 88: Ascepion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 964

Table 89: Astellas' Included Breast Cancer Drugs and Competitive Fall-Out 967

Table 90: Astex Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 972

Table 91: AstraZeneca's Included Breast Cancer Drugs and Competitive Fall-Out 978

Table 92: Attenuon's Included Breast Cancer Drugs and Competitive Fall-Out 986

Table 93: AVI BioPharma's Included Breast Cancer Drugs and Competitive Fall-Out 988

Table 94: Basilea Pharmaceutica's Included Breast Cancer Drugs and Competitive Fall-Out 992

Table 95: Bavarian Nordic's Included Breast Cancer Drugs and Competitive Fall-Out 996

Table 96: Bayer's Included Breast Cancer Drugs and Competitive Fall-Out 1001

Table 97: Beta Pharma's Included Breast Cancer Drugs and Competitive Fall-Out 1006

Table 98: Betagenon's Included Breast Cancer Drugs and Competitive Fall-Out 1008

Table 99: Biogen Idec's Included Breast Cancer Drugs and Competitive Fall-Out 1011

Table 100: BioMarin's Included Breast Cancer Drugs and Competitive Fall-Out 1014

Table 101: Bionovo's Included Breast Cancer Drugs and Competitive Fall-Out 1017

Table 102: BioSante's Included Breast Cancer Drugs and Competitive Fall-Out 1020

Table 103: Biotecnol's Included Breast Cancer Drugs and Competitive Fall-Out 1024

Table 104: Boehringer Ingelheim's Included Breast Cancer Drugs and Competitive Fall-Out 1027

Table 105: Bristol-Myers Squibb's Included Breast Cancer Drugs and Competitive Fall-Out 1033

Table 106: BTG's Included Breast Cancer Drugs and Competitive Fall-Out 1042

Table 107: Callisto Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1047

Table 108: Cancer Research Technology's Included Breast Cancer Drugs and Competitive Fall-Out 1050

Table 109: Cel-Sci's Included Breast Cancer Drugs and Competitive Fall-Out 1053

Table 110: Celgene's Included Breast Cancer Drugs and Competitive Fall-Out 1057

Table 111: Cell Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1063

Table 112: Celldex Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1066

Table 113: Celltrion's Included Breast Cancer Drugs and Competitive Fall-Out 1070

Table 114: Celsion's Included Breast Cancer Drugs and Competitive Fall-Out 1074

Table 115: Celtic Pharma's Included Breast Cancer Drugs and Competitive Fall-Out 1076

Table 116: Center of Molecular Immunology's Included Breast Cancer Drugs and Competitive Fall-Out 1079

Table 117: Chemokine Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1082

Table 118: Chiesi's Included Breast Cancer Drugs and Competitive Fall-Out 1085

Table 119: Chong Kun Dang's Included Breast Cancer Drugs and Competitive Fall-Out 1089

Table 120: CompleGen's Included Breast Cancer Drugs and Competitive Fall-Out 1091

Table 121: Curis' Included Breast Cancer Drugs and Competitive Fall-Out 1094

Table 122: Cyclacel's Included Breast Cancer Drugs and Competitive Fall-Out 1096

Table 123: Cylene Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1098

Table 124: Cynvec's Included Breast Cancer Drugs and Competitive Fall-Out 1100

Table 125: CytImmune Sciences' Included Breast Cancer Drugs and Competitive Fall-Out 1103

Table 126: Cytokinetics' Included Breast Cancer Drugs and Competitive Fall-Out 1107

Table 127: CytRx's Included Breast Cancer Drugs and Competitive Fall-Out 1111

Table 128: Daiichi Sankyo's Included Breast Cancer Drugs and Competitive Fall-Out 1115

Table 129: Dainippon Sumitomo Pharma's Included Breast Cancer Drugs and Competitive Fall-Out 1120

Table 130: Debiopharm's Included Breast Cancer Drugs and Competitive Fall-Out 1123

Table 131: Dendreon's Included Breast Cancer Drugs and Competitive Fall-Out 1127

Table 132: Domainex's Included Breast Cancer Drugs and Competitive Fall-Out 1130

Table 133: Dong-A's Included Breast Cancer Drugs and Competitive Fall-Out 1134

Table 134: Dongkook Pharm's Included Breast Cancer Drugs and Competitive Fall-Out 1137

Table 135: Douglas' Included Breast Cancer Drugs and Competitive Fall-Out 1140

Table 136: ECI's Included Breast Cancer Drugs and Competitive Fall-Out 1142

Table 137: Eisai's Included Breast Cancer Drugs and Competitive Fall-Out 1145

Table 138: Elara Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1150

Table 139: ElexoPharm's Included Breast Cancer Drugs and Competitive Fall-Out 1152

Table 140: Eli Lilly's Included Breast Cancer Drugs and Competitive Fall-Out 1156

Table 141: Endoceutics' Included Breast Cancer Drugs and Competitive Fall-Out 1163

Table 142: Enkam Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1165

Table 143: EntreMed's Included Breast Cancer Drugs and Competitive Fall-Out 1167

Table 144: Enzon's Included Breast Cancer Drugs and Competitive Fall-Out 1170

Table 145: Epeius Biotechnologies' Included Breast Cancer Drugs and Competitive Fall-Out 1172

Table 146: EpiCept's Included Breast Cancer Drugs and Competitive Fall-Out 1176

Table 147: Epizyme's Included Breast Cancer Drugs and Competitive Fall-Out 1178

Table 148: Esperance Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1180

Table 149: Etubics' Included Breast Cancer Drugs and Competitive Fall-Out 1184

Table 150: Eucodis' Included Breast Cancer Drugs and Competitive Fall-Out 1187

Table 151: Exelixis' Included Breast Cancer Drugs and Competitive Fall-Out 1191

Table 152: Expression Drug Designs' Included Breast Cancer Drugs and Competitive Fall-Out 1196

Table 153: Formula Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1199

Table 154: Fresenius' Included Breast Cancer Drugs and Competitive Fall-Out 1203

Table 155: Galectin Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1206

Table 156: Galena Biopharma's Included Breast Cancer Drugs and Competitive Fall-Out 1211

Table 157: Genentech's Included Breast Cancer Drugs and Competitive Fall-Out 1216

Table 158: Generex's Included Breast Cancer Drugs and Competitive Fall-Out 1220

Table 159: Genmab's Included Breast Cancer Drugs and Competitive Fall-Out 1224

Table 160: Genta's Included Breast Cancer Drugs and Competitive Fall-Out 1227

Table 161: GenVec's Included Breast Cancer Drugs and Competitive Fall-Out 1229

Table 162: Geron's Included Breast Cancer Drugs and Competitive Fall-Out 1232

Table 163: Gilead Sciences' Included Breast Cancer Drugs and Competitive Fall-Out 1236

Table 164: GlaxoSmithKline's Included Breast Cancer Drugs and Competitive Fall-Out 1240

Table 165: GlyTag's Included Breast Cancer Drugs and Competitive Fall-Out 1245

Table 166: Got-a-Gene's Included Breast Cancer Drugs and Competitive Fall-Out 1249

Table 167: Gradalis' Included Breast Cancer Drugs and Competitive Fall-Out 1251

Table 168: Harbor BioSciences' Included Breast Cancer Drugs and Competitive Fall-Out 1254

Table 169: Heidelberg Pharma's Included Breast Cancer Drugs and Competitive Fall-Out 1257

Table 170: Hoffmann-La Roche's Included Breast Cancer Drugs and Competitive Fall-Out 1263

Table 171: Hospira's Included Breast Cancer Drugs and Competitive Fall-Out 1274

Table 172: Idera Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1277

Table 173: Immunocore's Included Breast Cancer Drugs and Competitive Fall-Out 1280

Table 174: ImmunoGen's Included Breast Cancer Drugs and Competitive Fall-Out 1283

Table 175: Immunomedics' Included Breast Cancer Drugs and Competitive Fall-Out 1287

Table 176: ImmuPharma's Included Breast Cancer Drugs and Competitive Fall-Out 1290

Table 177: Immutep's Included Breast Cancer Drugs and Competitive Fall-Out 1292

Table 178: Incyte Corporation's Included Breast Cancer Drugs and Competitive Fall-Out 1295

Table 179: Inex's Included Breast Cancer Drugs and Competitive Fall-Out 1298

Table 180: Infinity Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1302

Table 181: Innate Pharma's Included Breast Cancer Drugs and Competitive Fall-Out 1304

Table 182: InNexus Biotechnology's Included Breast Cancer Drugs and Competitive Fall-Out 1308

Table 183: Inovio's Included Breast Cancer Drugs and Competitive Fall-Out 1310

Table 184: Insmed's Included Breast Cancer Drugs and Competitive Fall-Out 1313

Table 185: Insys Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1318

Table 186: Intarcia Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1322

Table 187: Intezyne Technologies' Included Breast Cancer Drugs and Competitive Fall-Out 1326

Table 188: Intradigm's Included Breast Cancer Drugs and Competitive Fall-Out 1329

Table 189: Introgen Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1332

Table 190: Ipsen's Included Breast Cancer Drugs and Competitive Fall-Out 1336

Table 191: Isis Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1339

Table 192: Jina Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1342

Table 193: Johnson & Johnson's Included Breast Cancer Drugs and Competitive Fall-Out 1344

Table 194: Kiadis' Included Breast Cancer Drugs and Competitive Fall-Out 1347

Table 195: Kinex's Included Breast Cancer Drugs and Competitive Fall-Out 1349

Table 196: Kyowa Hakko Kirin's Included Breast Cancer Drugs and Competitive Fall-Out 1353

Table 197: Leo's Included Breast Cancer Drugs and Competitive Fall-Out 1357

Table 198: Ligand's Included Breast Cancer Drugs and Competitive Fall-Out 1360

Table 199: Lorus Therapeutics' Included Breast Cancer Drugs and Competitive Fall-Out 1363

Table 200: MacroGenics' Included Breast Cancer Drugs and Competitive Fall-Out 1367

Table 201: Marillion Pharmaceuticals' Included Breast Cancer Drugs and Competitive Fall-Out 1370

Table 202: Marina Biotech's Included Breast Cancer Drugs and Com

To order this report:Drug and Medication Industry: Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software
2. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Volpara Breast Density Software
5. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
8. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
9. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
10. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
11. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):